Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.51 |
| ▸ | AKT2 | P31751 | 18/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12759376 | 0.87 | AKT1 (0.53) | AKT1AKT2KCNH2 | |
| SCHEMBL1501777 | 0.82 | AKT1 (0.58) | AKT1AKT2KCNH2 | |
| SCHEMBL1501764 | 0.81 | AKT1 (0.74) | AKT1AKT2KCNH2 | |
| SCHEMBL1501801 | 0.81 | AKT1 (0.44) | AKT1AKT2KCNH2 | |
| SCHEMBL5493712 | 0.80 | AKT1 (0.49) | AKT1AKT2KCNH2 | |
| SCHEMBL1349923 | 0.80 | SGK1 (0.40) | — | |
| SCHEMBL1501601 | 0.79 | AKT1 (0.56) | AKT1AKT2KCNH2 | |
| SCHEMBL12759328 | 0.79 | AKT1 (0.53) | AKT1AKT2 | |
| SCHEMBL12759248 | 0.78 | AKT1 (0.68) | AKT1AKT2KCNH2 | |
| SCHEMBL1501703 | 0.78 | AKT1 (0.54) | AKT1AKT2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910561-B2 | Cancer; such as 3-phenyl-2-(4-{[4-(5-pyridin-2-yl-1H-1,2,4-triazol-3-yl)piperidin-1-yl]methyl}phenyl)-1,6-naphthyridin-5(6H)-one; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, greater selectivity, enhanced pharmacokinetic properties, lack of off target activity | MERCK SHARP & DOHME CORP. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080287457-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287457-A1 | Inhibitors of Akt Activity | AKT3, MTOR, STK3 | AKT1 11/4885AKT2 7/4885KCNH2 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.